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Introduction. High levels of advanced glycated products (AGEs) and fibroblast growth factor-23 (FGF-23) are 
recognized as important cardiovascular risk factors. In chronic kidney disease (CKD), FGF-23 increases as a 
compensatory mechanism to keep normal phosphate and AGEs accumulate due both to the increased formation and  
reduced elimination. Being by-products of hyperglycemia, the formation of AGEs is further increased in patients with 
diabetes mellitus (DM). Recently, AGEs have been shown to induce cardiac remodeling in a mouse model of renal 
failure by promoting  FGF-23 expression. Our aim was to explore whether Chronic Kidney Disease on dialysis (CKD-
G5D) with DM suffer of an increased cardiac remodeling due to the to increased AGEs formation and the further  
amplification of  the FGF-23 response. 
Methods. We quantified plasma levels of glycated albumin (GA), sRAGE, the decoy receptor  for AGEs, c-terminal 
FGF-23 (cFGF23), brain natriuretic peptide (BNP) and the inflammatory mediators C-reactive protein,  tumor necrosis 
factor alpha and pentraxin-3 in 24 CKD-G5D patients with DM and 52 without DM.  
Results. The levels of sRAGE, cFGF-23, BNP and the pro-inflammatory markers evaluated were over the ranges of 
normality in both DM and non-DM groups. GA and sRAGE were increased in DM CKD-G5D compared to non-DM 
CKD-G5D patients but cFGF-23 did not differ between the two groups. Similarly, the concentrations of the pro-
inflammatory molecules and BNP were almost the same in the two groups. 
Conclusions. The up-regulation of sRAGE could be a counteract-system against glycated products. sRAGE, by 
blocking glycated products, could reduce the activation of various damaging cellular mechanisms, including an 
increased stimulation of cFGF-23and  inflammatory mediators. Indeed, since AGEs accumulation is a risk factor for 
development and progression of heart failure, the lack of difference also in BNP levels between the two groups 
reinforces the hypothesis of a protective role of sRAGE in DM CKD-G5D patients.  
 
